Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

OMERBullishResearch Analysisnews

High materiality8/10

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Jun 10, 2025, 1:17 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A Buy rating with a high target price indicates potential upside. Historical examples show FDA approvals can lead to significant stock increases.

AI summary

What happened, with direct paths to the underlying reporting

H.C. Wainwright rates OMER as Buy with a $9 price target. Omeros approaches FDA decision on Narsoplimab expected September 25. Narsoplimab's approval could unlock $500-$1B commercial opportunity. Omeros is scaling back other initiatives to focus on Narsoplimab launch. Despite past losses, OMER shares are trending up by 3.58%.

H.C. Wainwright rates OMER as Buy with a $9 price target.
Omeros approaches FDA decision on Narsoplimab expected September 25.
Narsoplimab's approval could unlock $500-$1B commercial opportunity.
Omeros is scaling back other initiatives to focus on Narsoplimab launch.
Despite past losses, OMER shares are trending up by 3.58%.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

EMA concerns on Yartemlea weigh on Omeros post-launch earnings

Omeros prices transplant complication drug at $36,000 per dose

US FDA approves Omeros' drug to treat dangerous transplant complication

Omeros Soars Over 150% After $2.1B Novo Nordisk Deal; Long-term Gains Questioned